Completed PHASE2 INTERVENTIONAL 2-arm NCT01440816

IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer (MCC)

A Phase II Study of Intratumoral Injection of Interleukin-12 Plasmid and in Vivo Electroporation in Patients With Merkel Cell Carcinoma

Sponsor: National Cancer Institute (NCI)

Conditions Merkel Cell Carcinoma

Interventions OncoSec Medical System (OMS) Tavokinogene Telseplasmid (tavo)

Updated 9 times since 2017 Last updated: May 11, 2023 Started: Jan 3, 2012 Primary completion: Apr 10, 2015 Completion: Apr 10, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Merkel Cell Carcinoma and is currently completed. National Cancer Institute (NCI) leads this study, which shows 9 recorded versions since 2012 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jun 2023 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Jun 2023 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Dec 2017 — Jun 2018 [monthly]

Completed PHASE2
May 2017 — Dec 2017 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Feb 2017 — May 2017 [monthly]

Active Not Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE2

First recorded

Jan 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
OncoSec Medical Incorporated

Data source: OncoSec Medical Incorporated

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seattle, United States